The National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of Russia has been developing a drug against the Marburg virus since 2022. The initial phase of clinical trials has recently concluded, affirming both the safety of the vaccine and its effectiveness in generating an immune response, as reported by Lexander Gintsburg, the director of the center.
The project was put on hold because there was no immediate threat. However, in light of recent reports indicating the swift spread of the disease in Africa, efforts to resume the work may soon be underway. According to experts, it will take from 9 to 12 months to complete the development.
